About the organization
Basic details : To develop treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and primary progressive multiple sclerosis (PPMS).We are passionate about improving patients’ quality of life and are well on the way to becoming leaders in rare mitochondrial and neuromuscular disorders.
Mission : To develop treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and primary progressive multiple sclerosis (PPMS).
Vision : We are passionate about improving patients’ quality of life and are well on the way to becoming leaders in rare mitochondrial and neuromuscular disorders.
Organization primary focus : Neuromuscular and neuro-ophthalmological rare diseases
Contact information
| Website | http://www.santhera.com |
|---|---|
| Address | Hammerstrasse 49, CH-4410 - Liestal, |
| Contact us for | General partnerships , Good case practice sharing , Opportunities for patient engagement collaborations , Speaking opportunities , Participation in task forces and related initiatives, publications related to patient centricity and engagement within industry |
| Organization main contact email | vanessa.dosreisferreira@santhera.com |
Initiatives
The 1st European Patient Groups Advisory Board meeting for Leber’s Hereditary Optic Neuropathy (LHON) joined patient groups from 7 different...
OBJECTIVE By using the PE Quality Guidance that was co-created with patients and other stakeholders in the patient engagement (PE) and medi...
OBJECTIVE By using the PE Quality Guidance that was co-created with patients and other stakeholders in the patient engagement (PE) and medi...
Users
Vanessa Ferreira
Patient Advocacy Manager
- Organization
- Santhera Pharmaceuticals